Modeling Neurodegenerative Disorders for Developing Cannabinoid-Based Neuroprotective Therapies.

Authors: Javier Fernández-Ruiz, María Gómez-Ruiz, Concepción García, Mariluz Hernández, José A. Ramos
Methods in Enzymology, 2017

The increase in lifespan during the last 50 years, mainly in developed countries, has originated a progressive elevation in the incidence of chronic neurodegenerative disorders, for which aging is the key risk factor. This fact will definitively become the major biomedical cha…

Cannabinoid Type-2 Receptor Drives Neurogenesis and Improves Functional Outcome After Stroke.

Authors: Isabel Bravo-Ferrer, María I. Cuartero , Juan G. Zarruk, Jesús M. Pradillo, Olivia Hurtado, et al
Stroke, January 2017

BACKGROUND AND PURPOSE: Stroke is a leading cause of adult disability characterized by physical, cognitive, and emotional disturbances. Unfortunately, pharmacological options are scarce. The cannabinoid type-2 receptor (CB2R) is neuroprotective in acute experimental stroke by …

Integrating cannabis into clinical cancer care.

Authors: D.I. Abrams
Current Oncology, March 2016

Cannabis species have been used as medicine for thousands of years; only since the 1940s has the plant not been widely available for medical use. However, an increasing number of jurisdictions are making it possible for patients to obtain the botanical for medicinal use. For t…

Cannabinoids to treat spinal cord injury.

Authors: Angel Arevalo-Martin, Eduardo Molina-Holgado, Daniel Garcia-Ovejero
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 4 January 2016

Spinal cord injury (SCI) is a devastating condition for which there is no standard treatment beyond rehabilitation strategies. In this review, we discuss the current knowledge on the use of cannabinoids to treat this condition. The endocannabinoid system is expressed in the in…

Molecular Targets of Cannabidiol in Neurological Disorders.

Authors: Clementino Ibeas Bih, Tong Chen, Alistair V. W. Nunn, Michaël Bazelot, et al
Neurotherapeutics, October 2015

Cannabis has a long history of anecdotal medicinal use and limited licensed medicinal use. Until recently, alleged clinical effects from anecdotal reports and the use of licensed cannabinoid medicines are most likely mediated by tetrahydrocannabinol by virtue of: 1) this canna…

Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results.

Authors: Sunil Aggarwal
Clinical Journal of Pain, February 2013

OBJECTIVES: This article attempts to cover pragmatic clinical considerations involved in the use of cannabinergic medicines in pain practice, including geographical and historical considerations, pharmacokinetics, pharmacodynamics, adverse effects, drug interactions, indicatio…